Le Lézard
Classified in: Health
Subjects: NPT, LEG, EXE, AVO

Hawaii Health Measure Includes Last-Minute Provision Benefiting Big Tobacco; Legislature Should Revisit Measure and Repair the Damage


WASHINGTON, July 13, 2018 /PRNewswire-USNewswire/ -- House Bill 1895, an otherwise well-meaning and worthy bill to fund needed kidney dialysis centers in the state, contains a last-minute provision, snuck into the bill behind closed doors by special interests without public discussion or review, that will greatly harm public health and help the tobacco industry. This provision would block (preempt) county governments in Hawaii from passing their own laws to reduce tobacco use, including measures addressing the sale of candy-flavored tobacco products and menthol cigarettes that attract kids.

Campaign for Tobacco-Free Kids logo. (PRNewsFoto/Campaign for Tobacco-Free Kids)

It is truly outrageous that the tobacco industry worked in secret to include this damaging, last-minute provision in a bill aimed at improving public health and shows how far the industry is willing to go to preserve its profits at the expense of kids and lives. We are disappointed the legislature acquiesced to this damaging provision and urge them to revisit this legislation next year, remove the offending provision and tell Big Tobacco that protecting Hawaii's kids comes first.

The special-interest tobacco industry provision was added at the last minute of the legislative session ?with no time for public comment. It is a cruel irony that a bill devoted to improving public health now includes a provision that would do great harm to public health by preventing localities from combating the state's No. 1 preventable cause of death ? tobacco use. Localities should be able to determine their own tobacco policies and the legislature should oppose attempts to stifle these efforts to protect kids and save lives. Some 1,400 Hawaii residents die each year from smoking, and 21,000 kids alive today in Hawaii will die prematurely from smoking if nothing is done to reduce tobacco use.

While we applaud efforts to address the pressing health concern of kidney dialysis, the preemption provision in HB1895 will severely impede future progress to save more lives from tobacco use. Preemption measures have long been a favored tobacco industry tactic for blocking tobacco control efforts because the industry knows that localities have played a critical role in reducing tobacco use in Hawaii and across the nation. From smoke-free air regulations to raising the tobacco age to 21, Hawaii counties took the lead in passing local ordinances before the state took action. Across the country, more and more communities are restricting the sale of candy-flavored tobacco products that the industry uses to lure kids into a lifetime of addiction. By preventing local governments from taking necessary and bold moves to protect the health and safety of their communities from tobacco, HB1895 would keep Hawaii from being a leader in this critical area and could slow progress in reducing tobacco use.

SOURCE Campaign for Tobacco-Free Kids


These press releases may also interest you

at 07:05
Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically...

at 07:05
Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its...

at 07:05
Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology ? activation lethality ? which targets cancer's surprising vulnerability to oncogene overactivation. Leveraging this next-generation approach,...

at 07:05
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential...

at 07:00
Blueprint Medicines Corporation today reported financial results, provided a business update for the first quarter ended...

at 07:00
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary DiffuSpheretm technology to optimize drug delivery for applications with significant unmet need, today announced the...



News published on and distributed by: